Warner K. Huh, MD, UAB

home / authors / warner-k-huh-md-uab

Articles

Cervical Cancer Management: Looking Toward the Future of Care

Bradley J. Monk, MD, FACOG, FACS;Warner K. Huh, MD, UAB;Bhavana Pothuri, MD;Krishnansu S. Tewari, MD;Premal H. Thaker, MD, MS

December 8th 2021

Closing out their discussion on the management of cervical cancer, panelists share their excitement for future evolutions in care.

Metastatic Cervical Cancer: Practical Considerations for Tisotumab Vedotin Use

Bradley J. Monk, MD, FACOG, FACS;Warner K. Huh, MD, UAB;Bhavana Pothuri, MD;Krishnansu S. Tewari, MD;Premal H. Thaker, MD, MS

December 8th 2021

Experts share their experience and thoughts on the use of tisotumab vedotin as the management of metastatic cervical cancer continues to evolve.

Metastatic Cervical Cancer: ADC Adverse Event Management

Bradley J. Monk, MD, FACOG, FACS;Warner K. Huh, MD, UAB;Bhavana Pothuri, MD;Krishnansu S. Tewari, MD;Premal H. Thaker, MD, MS

December 2nd 2021

Considerations for adverse event management with tisotumab vedotin use in patients with metastatic cervical cancer.

Tisotumab Vedotin: A Second-Line ADC Approval in Metastatic Cervical Cancer

Bradley J. Monk, MD, FACOG, FACS;Warner K. Huh, MD, UAB;Bhavana Pothuri, MD;Krishnansu S. Tewari, MD;Premal H. Thaker, MD, MS

December 2nd 2021

Shared insight on the approval of tisotumab vedotin, an antibody-drug conjugate, in the second-line setting of metastatic cervical cancer.

Metastatic Cervical Cancer: Moving Immune Checkpoint Inhibition to the Front Line

Bradley J. Monk, MD, FACOG, FACS;Warner K. Huh, MD, UAB;Bhavana Pothuri, MD;Krishnansu S. Tewari, MD;Premal H. Thaker, MD, MS

November 24th 2021

Panelists reflect on the potential for immune checkpoint inhibition to become a frontline option in metastatic cervical cancer, and what that means for the second-line setting.

Second-Line Immune Checkpoint Inhibition in Metastatic Cervical Cancer

Bradley J. Monk, MD, FACOG, FACS;Warner K. Huh, MD, UAB;Bhavana Pothuri, MD;Krishnansu S. Tewari, MD;Premal H. Thaker, MD, MS

November 24th 2021

An overview of second-line immune checkpoint inhibitor use in patients with relapsed or refractory metastatic cervical cancer.

Unmet Needs in Second-Line Therapy for Metastatic Cervical Cancer

Bradley J. Monk, MD, FACOG, FACS;Warner K. Huh, MD, UAB;Bhavana Pothuri, MD;Krishnansu S. Tewari, MD;Premal H. Thaker, MD, MS

November 18th 2021

Switching its focus to second-line therapy for metastatic cervical cancer, the panel reviews an unmet need of effective therapy in this setting.

Metastatic Cervical Cancer: Interpreting Data From KEYNOTE-826

Bradley J. Monk, MD, FACOG, FACS;Warner K. Huh, MD, UAB;Bhavana Pothuri, MD;Krishnansu Tewari, MD;Premal H. Thaker, MD, MS

November 18th 2021

Experts take a closer look at the data points from KEYNOTE-826 to consider pembrolizumab’s potential role in metastatic cervical cancer management.

KEYNOTE-826: Immune Checkpoint Inhibition in Metastatic Cervical Cancer

Bradley J. Monk, MD, FACOG, FACS;Warner K. Huh, MD, UAB;Bhavana Pothuri, MD;Krishnansu S. Tewari, MD;Premal H. Thaker, MD, MS

November 10th 2021

Considerations for the KEYNOTE-826 trial, which tested pembrolizumab in combination with chemotherapy in patients with metastatic cervical cancer.

Chemotherapy and Antiangiogenesis Therapy in Metastatic Cervical Cancer

Bradley J. Monk, MD, FACOG, FACS;Warner K. Huh, MD, UAB;Bhavana Pothuri, MD;Krishnansu S. Tewari, MD;Premal H. Thaker, MD, MS

November 10th 2021

Looking at the current treatment landscape in metastatic cervical cancer, experts consider the role of frontline chemotherapy and antiangiogenesis therapy.

Ongoing Clinical Trials in Locally Advanced Cervical Cancer

Bradley J. Monk, MD, FACOG, FACS;Warner K. Huh, MD, UAB;Bhavana Pothuri, MD;Krishnansu S. Tewari, MD;Premal H. Thaker, MD, MS

November 3rd 2021

Closing out their discussion on locally advanced cervical cancer, panelists discuss ongoing clinical trials and the potential of the involved novel therapies.